What Rodon Biologics does

Rodon Biologics is a Portugal-based biotech contract research and contract development and manufacturing organization (CRO/CDMO) providing integrated biologics development and manufacturing services for third-party biopharmaceutical and biotechnology clients. Operating from facilities in Barcarena (headquarters, within IBERFAR's pharmaceutical complex) and Oeiras (R&D) in the Lisbon region, the company offers an end-to-end service portfolio spanning protein engineering, cell line development, process development, GMP manufacturing, and analytical characterization for recombinant proteins, monoclonal antibodies, multispecific antibodies, cytokines, growth factors, and enzymes.

The company operates dual expression platforms using mammalian (CHO, HEK293) and microbial (E. coli, Pichia pastoris, Saccharomyces cerevisiae) systems, supported by downstream processing, formulation development, ICH Q5C-aligned stability testing, and a broad analytical characterization stack (HPLC, ELISA, SPR, mass spectrometry, glycan profiling, cell-based potency assays). Its cell line development workflow is reported to produce high-yielding single-cell clones within 16-20 weeks, achieve gram-per-liter titers within 9-12 weeks from high-producing pools, and maintain genetic stability for up to 60 generations. Service offerings are now organized into two lines — Biopharma Services and Synthetic Biology Services — covering the full gene-to-GMP value chain.

Rodon runs a fee-for-service, project-based revenue model with quote-based pricing typical of CDMO engagements, and its go-to-market blends enterprise field sales with heavy event-driven business development (BIO-Europe, PEGS Europe, Festival of Biologics, SynBioBeta, BioProcess International). The company has been privately held throughout its history: it was acquired by IBERFAR Group in December 2018, joined Portugal's P-BIO industry association in August 2021, and was acquired by Chrysea Limited (with Juvenescence-backed financing) in February 2024, providing access to synthetic biology capabilities while Rodon continues to operate independently. The company employs 11-50 people and holds the Portuguese Selo ID R&D certification from ANI, which enables client access to SIFIDE II tax incentive programs.

Name

Rodon Biologics

Legal name

RDN Serviços de Biotecnologia, Unipessoal Lda

Website

https://rodonbiologics.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Portugal-based biotech CRO/CDMO providing end-to-end biologics development and manufacturing services — including protein engineering, cell line and process development, and GMP production — for biopharmaceutical and biotechnology clients globally.

Ownership category

akta.pro rank

Product category

Biologics Contract Development and Manufacturing (CRO/CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Biologics contract manufacturing
• Biopharmaceutical development services
• Cell line development
• Protein engineering services
• GMP clinical manufacturing

Headquarters

HQ city

Barcarena

HQ country

Portugal

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. CRO/CDMO Services: Fee-for-service contract research and manufacturing organization providing end-to-end biologics development services including protein engineering, cell line development, process development, GMP manufacturing, and analytical services. Revenue generated through project-based contracts with biopharmaceutical clients.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Rodon Biologics is a biotech CRO/CDMO providing integrated contract research, development, and manufacturing services for recombinant biologics, covering protein engineering, microbial and mammalian cell line development, upstream and downstream process development, GMP manufacturing for clinical supply, analytical characterization, formulation, and ICH-compliant stability testing. Its offering serves biopharmaceutical and biotechnology companies developing monoclonal antibodies, multispecific antibodies, recombinant proteins, enzymes, cytokines, and growth factors for discovery through clinical stages.

Product overview

Rodon Biologics is a biotech CRO/CDMO (Contract Research Organization/Contract Development and Manufacturing Organization) providing integrated biologics development and manufacturing services. The company offers an end-to-end service portfolio spanning protein engineering, cell line development (microbial and mammalian systems), process development, GMP manufacturing, and analytical characterization. Key services include Protein Engineering Services, Protein Production Services, Cell Line Development Services, Process Development, Manufacture (including GMP for clinical trials), Cell-Based Assays, Analytical Characterisation Services, Formulation Development, Stability Testing, and Downstream Processing Services. The company specializes in microbial fermentation (E. coli, yeast) and mammalian cell culture (CHO cells) for producing monoclonal antibodies, multispecific antibodies, recombinant proteins, enzymes, cytokines, and growth factors.

Differentiator

Problem solved

Functional benefit

Products and services

• Protein Engineering Services Targeted modifications to change the properties of therapeutic proteins, including antibody humanization of monoclonal antibodies (mAbs) and protein stabilization. Intended for biopharmaceutical and biotech teams developing engineered biologics for research, diagnostic, or therapeutic applications.
• Protein Production Services Custom recombinant protein expression and purification from different expression systems for research, preclinical, and clinical use. Serves clients requiring milligram-to-gram quantities of recombinant proteins.
• Process Development Development, optimization, and characterization of a scalable process for manufacture and formulation of biologics, supporting tech transfer from bench to GMP scale. Targeted at biopharmaceutical sponsors moving candidates toward clinical manufacture.
• Manufacture Manufacturing and supply of finished proteins for discovery, research, preclinical, and clinical use, including GMP production for clinical trials. Intended for biopharmaceutical clients requiring cGMP-grade biologic material.
• Cell-Based Assays Cell-based assays used to test and assure the biological activity, potency, and stability of proteins. Serves biologics developers requiring functional release and characterization data.
• Analytical Characterisation Services Physicochemical methods supporting in-process control, release, characterization, and stability to assure protein quality for clinical and commercial programs.
• Formulation Development Formulation development selecting the best formulation for compounds, focused on activity and optimal stability. Targeted at sponsors preparing candidates for clinical or commercial use.
• Stability Testing Biologics real-time and accelerated stability testing to predict and validate shelf life and in-use stability of products, executed under ICH-compliant conditions.
• Cell Line Development Services Development of stable cell lines to produce recombinant proteins, including antibodies and small molecules, using both microbial and mammalian expression systems.
• Cell Line and Process Development Integrated service providing stable cell line generation for recombinant proteins and antibody production combined with development, optimization, and characterization of scalable processes.
• Microbial Fermentation Biosynthetic production using microbial fermentation for recombinant proteins, enzymes, and biopharmaceuticals in E. coli, Pichia pastoris, and Saccharomyces cerevisiae systems.
• Mammalian Cell Culture Services Production of complex biologics including monoclonal antibodies, multispecific antibodies, and recombinant proteins using mammalian cell culture with proper folding, glycosylation, and post-translational modifications.
• Downstream Processing Services Efficient and cost-effective purification of biologics, enabling production of high-quality biosynthetic products at commercial scale.
• Manufacturing Optimization and Troubleshooting Optimization of manufacturing processes and troubleshooting services to ensure product quality, consistency, and maximize production output.
• Analytical Services Comprehensive analytical services tailored for the biosynthetic industry, including concentration, purity, identity, and activity testing for recombinant proteins.

Quantifiable outcome

• High-producing single-cell clones generated in 16-20 weeks
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and former.

• Bac3Gel LdacoreStrategic or Co-development Partner · 12 March 2025Rodon Biologics is partnering with Bac3Gel Lda to test bacterial growth using their innovative growth-boosting beads - a cutting-edge technology designed to enhance microbiota proliferation in vitro. This partnership opens new avenues for optimizing bacterial culture conditions, improving bioprocess efficiency and exploring novel applications in microbiome research.
• P-BIO (Portugal's Biotechnology Industry Organization)coreStrategic or Co-development Partner · 6 August 2021Rodon Biologics became a member of P-BIO, Portugal's Biotechnology Industry Organization. P-BIO develops an environment favorable to the creation and growth of biotech startups, promoting corporate development domestically and internationally. As a member of EuropaBio, P-BIO links companies with government, investors, and regulatory agencies.
• IBERFAR GROUPformerOthersIBERFAR acquired Rodon Biologics in December 2018. Rodon moved to IBERFAR's facilities in Barcarena, Portugal. IBERFAR is a privately-owned Portuguese pharmaceutical group founded in 1924, specializing in manufacturing and packaging of pharmaceutical products. Rodon was subsequently sold to Chrysea Limited in February 2024.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• AGC Biologics: Mid-size global CDMO with mammalian and microbial biologics manufacturing services including cell-line development and GMP production. Comparable in offering portfolio though larger in scale and geographic footprint than Rodon.
• Biovian: Finnish boutique biologics CDMO offering GMP manufacturing, cell line development, and viral vectors for biotech clients. Closely comparable in size and European base to Rodon, covering similar recombinant protein services for small-to-mid biopharma clients.
• Enzene Biosciences: Biotecnol-affiliated CDMO offering biologics manufacturing, microbial fermentation, and continuous bioprocessing services for biopharma. Comparable in scope to Rodon's microbial fermentation and mammalian cell culture capabilities, though with a different technology positioning.
• Polpharma Biologics: European-focused biologics CDMO with capabilities in cell line development, process development, and GMP manufacturing of recombinant proteins and monoclonal antibodies. Direct competitor for mid-sized European biopharma contracts.
• ProBioGen: German biologics CDMO specializing in mammalian cell line development, GMP manufacturing, and proprietary expression technologies for antibodies and recombinant proteins. Comparable European competitor with similar focus on cell-line engineering and bioprocess services.

Broad incumbents

• Samsung Biologics: Large Korean CDMO providing contract development and manufacturing services for biologics including monoclonal antibodies and recombinant proteins. Competes for similar protein-based biologics programs, albeit typically at much larger commercial scales than Rodon handles.
• Lonza Group: Swiss-headquartered global leader in biologics CDMO with mammalian and microbial capabilities offering cell-line development, process development, and GMP manufacturing. Comparable as it competes for the same biopharma clients across the same biologics value chain, but at vastly larger scale across multiple geographies.
• WuXi Biologics: Global Chinese-origin biologics CDMO providing end-to-end biologics discovery, development and manufacturing services. Competes for similar client programs as Rodon in cell line development and GMP manufacturing, but at far larger scale and broader geographic reach.
• Eurofins Biopharma Product Testing: European-headquartered contract laboratory and biopharma services provider with biologics-focused analytical, formulation and stability testing offerings. Overlaps with Rodon's analytical characterization, formulation development, and stability testing services.

Emerging players

• Jubilant Biosys / Jubilant Pharmova: India-headquartered biologics CDMO with mammalian and microbial expression capabilities providing cell line development and GMP manufacturing. Comparable service portfolio to Rodon for recombinant proteins and antibodies, though at a different cost-structure tier.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCijQjUweOi0ZLXYvhI7OuNQ
• LinkedInpt.linkedin.com/company/rodon-biologics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rodon Biologics